Proteinase-Activated Receptor 2 (PAR2): A Challenging New Target for Treatment of Vascular Diseases
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
2769-2778
Author(s):
John J. McGuire
Therapeutic Potential of Inhibiting Brutons Tyrosine Kinase, (BTK)
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
1757-1766
Author(s):
A. O. Vassilev and F. M. Uckun
Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Journal:
Current Pharmaceutical Design
Volume:
10
Page:
1767-1784
Author(s):
M. Cetkovic-Cvrlje and H. E. Tibbles
Cardiovascular Alterations After Spinal Cord Injury: An Overview
Journal:
Current Medicinal Chemistry - Cardiovascular & Hematological Agents
Volume:
2
Page:
133-148
Author(s):
Guadalupe Bravo, Gabriel Guizar-Sahagun, Antonio Ibarra, David Centurion and Carlos M. Villalon
Endothelin Receptor Antagonists: A New Therapeutic Option for Improving the Outcome after Solid Organ Transplantation?
Journal:
Current Vascular Pharmacology
Volume:
1
Page:
281-299
Author(s):
Uwe Gottmann, Fokko J. van der Woude and Claude Braun
WITHDRAWN: Resveratrol-based Delivery Systems as Contemporary Nominees for Combating Pulmonary Diseases: A Comprehensive Review
Journal:
Current Drug Delivery
Volume:
21
Page:
1-1
Author(s):
Sara Ahmed, Mai Mansour*, Rania A.H. Ishak and Nahed D. Mortada